This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takemasa, I. Articles by Monden, M. Search for Related Content PubMed PubMed Citation Articles by Takemasa, I. Articles by Monden, M.

Overexpression of CDC25B Phosphatase as a Novel Marker of Poor Prognosis of Human Colorectal Carcinoma¹

Department of Surgery II, Osaka University Medical School, Osaka 565-0871, Japan [I. T., H. Y., M. S., M. O., S. N., Y. M., T. M., Y. T., I. S., H. S., M. M.]; Department of Surgery, Osaka National Hospital, Osaka 540-0006, Japan [N. K.]; Department of Pathology, School of Allied Health Science, Faculty of Medicine, Osaka University, Osaka 565-0871, Japan [N. M.]; and Department of Surgery, Kansai Rosai Hospital, Hyogo 660-0064, Japan [T. A., N. T.]

There is evidence to suggest that CDC25B phosphatase is an oncogenic protein. To elucidate the role of CDC25B in colorectal carcinoma, we examined the expression of CDC25B at the mRNA and protein levels. Reverse transcription-PCR assay indicated that CDC25B was overexpressed in tumor tissues relative to normal mucosa in 6 of 10 cases. Using immunohistochemistry, we identified high expression of CDC25B in 77 of 181 colorectal cases (43%). Univariate analysis showed that high expression was a significant predictor for poor prognosis compared with low expression (5-year survival rate; 59% versus 82%, respectively; P < 0.0001). Multivariate analysis indicated that CDC25B was an independent prognostic marker (risk ratio for death, 3.7; P < 0.0001) even after controlling for various factors such as lymph node metastasis, tumor size, degree of differentiation, and depth of invasion. Furthermore, the level of CDC25B expression clearly predicted the outcome of patients with Dukes’ B and Dukes’ C tumors. On the other hand, CDC25A mRNA was overexpressed in 9 of 10 colorectal cancer cases, and immunohistochemistry for CDC25A showed high expression in 52 of 111 cases (47%), but no significant correlation with prognosis. Our findings suggest that CDC25B is a novel independent prognostic marker of colorectal carcinoma and that it may be clinically useful for selecting patients who could benefit from adjuvant therapy.

This article has been cited by other articles:

				R.-q. Chen, Q.-k. Yang, B.-w. Lu, W. Yi, G. Cantin, Y.-l. Chen, C. Fearns, J. R. Yates III, and J.-D. Lee CDC25B Mediates Rapamycin-Induced Oncogenic Responses in Cancer Cells Cancer Res., March 15, 2009; 69(6): 2663 - 2668. [Abstract] [Full Text] [PDF]

				J.-Z. Shou, N. Hu, M. Takikita, M. J. Roth, L. L. Johnson, C. Giffen, Q.-H. Wang, C. Wang, Y. Wang, H. Su, et al. Overexpression of CDC25B and LAMC2 mRNA and Protein in Esophageal Squamous Cell Carcinomas and Premalignant Lesions in Subjects from a High-Risk Population in China Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1424 - 1435. [Abstract] [Full Text] [PDF]

				K. Ezumi, H. Yamamoto, K. Murata, M. Higashiyama, B. Damdinsuren, Y. Nakamura, N. Kyo, J. Okami, C. Y. Ngan, I. Takemasa, et al. Aberrant Expression of Connexin 26 Is Associated with Lung Metastasis of Colorectal Cancer Clin. Cancer Res., February 1, 2008; 14(3): 677 - 684. [Abstract] [Full Text] [PDF]

				S. K. Srivastava, P. Bansal, T. Oguri, J. S. Lazo, and S. V. Singh Cell Division Cycle 25B Phosphatase Is Essential for Benzo(a)Pyrene-7,8-Diol-9,10-Epoxide Induced Neoplastic Transformation Cancer Res., October 1, 2007; 67(19): 9150 - 9157. [Abstract] [Full Text] [PDF]

				H Nakabayashi, M Hara, and K Shimizu Prognostic significance of CDC25B expression in gliomas. J. Clin. Pathol., July 1, 2006; 59(7): 725 - 728. [Abstract] [Full Text] [PDF]

				Y. Seki, H. Yamamoto, C. Yee Ngan, M. Yasui, N. Tomita, K. Kitani, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, et al. Construction of a novel DNA decoy that inhibits the oncogenic {beta}-catenin/T-cell factor pathway. Mol. Cancer Ther., April 1, 2006; 5(4): 985 - 994. [Abstract] [Full Text] [PDF]

				A. Lindqvist, H. Kallstrom, and C. Karlsson Rosenthal Characterisation of Cdc25B localisation and nuclear export during the cell cycle and in response to stress J. Cell Sci., October 1, 2004; 117(21): 4979 - 4990. [Abstract] [Full Text] [PDF]

				M. Brisson, T. Nguyen, A. Vogt, J. Yalowich, A. Giorgianni, D. Tobi, I. Bahar, C. R. J. Stephenson, P. Wipf, and J. S. Lazo Discovery and Characterization of Novel Small Molecule Inhibitors of Human Cdc25B Dual Specificity Phosphatase Mol. Pharmacol., October 1, 2004; 66(4): 824 - 833. [Abstract] [Full Text] [PDF]

				M.-C. Brezak, M. Quaranta, O. Mondesert, M.-O. Galcera, O. Lavergne, F. Alby, M. Cazales, V. Baldin, C. Thurieau, J. Harnett, et al. A Novel Synthetic Inhibitor of CDC25 Phosphatases: BN82002 Cancer Res., May 1, 2004; 64(9): 3320 - 3325. [Abstract] [Full Text] [PDF]

				X. Xu, H. Yamamoto, M. Sakon, M. Yasui, C. Y. Ngan, H. Fukunaga, T. Morita, M. Ogawa, H. Nagano, S. Nakamori, et al. Overexpression of CDC25A Phosphatase Is Associated with Hypergrowth Activity and Poor Prognosis of Human Hepatocellular Carcinomas Clin. Cancer Res., May 1, 2003; 9(5): 1764 - 1772. [Abstract] [Full Text] [PDF]

				T. Oguri, S. V. Singh, K. Nemoto, and J. S. Lazo The Carcinogen (7R,8S)-Dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene Induces Cdc25B Expression in Human Bronchial and Lung Cancer Cells Cancer Res., February 15, 2003; 63(4): 771 - 775. [Abstract] [Full Text] [PDF]

				E. Melkun, M. Pilione, and R. F. Paulson A naturally occurring point substitution in Cdc25A, and not Fv2/Stk, is associated with altered cell-cycle status of early erythroid progenitor cells Blood, November 15, 2002; 100(10): 3804 - 3811. [Abstract] [Full Text] [PDF]

				S. Noura, H. Yamamoto, T. Ohnishi, N. Masuda, T. Matsumoto, O. Takayama, H. Fukunaga, Y. Miyake, M. Ikenaga, M. Ikeda, et al. Comparative Detection of Lymph Node Micrometastases of Stage II Colorectal Cancer by Reverse Transcriptase Polymerase Chain Reaction and Immunohistochemistry J. Clin. Oncol., October 15, 2002; 20(20): 4232 - 4241. [Abstract] [Full Text] [PDF]

				V. Baldin, K. Pelpel, M. Cazales, C. Cans, and B. Ducommun Nuclear Localization of CDC25B1 and Serine 146 Integrity Are Required for Induction of Mitosis J. Biol. Chem., September 13, 2002; 277(38): 35176 - 35182. [Abstract] [Full Text] [PDF]

				S. Noura, H. Yamamoto, Y. Miyake, B. no Kim, O. Takayama, I. Seshimo, M. Ikenaga, M. Ikeda, M. Sekimoto, N. Matsuura, et al. Immunohistochemical Assessment of Localization and Frequency of Micrometastases in Lymph Nodes of Colorectal Cancer Clin. Cancer Res., March 1, 2002; 8(3): 759 - 767. [Abstract] [Full Text] [PDF]

				Y. Sato, H. Sasaki, S. Kondo, I. Fukai, M. Kiriyama, Y. Yamakawa, and Y. Fujii Expression of the cdc25B mRNA Correlated with that of N-myc in Neuroblastoma Jpn. J. Clin. Oncol., September 1, 2001; 31(9): 428 - 431. [Abstract] [Full Text] [PDF]

				M.-S. Chen, J. Hurov, L. S. White, T. Woodford-Thomas, and H. Piwnica-Worms Absence of Apparent Phenotype in Mice Lacking Cdc25C Protein Phosphatase Mol. Cell. Biol., June 15, 2001; 21(12): 3853 - 3861. [Abstract] [Full Text]

				Y. Miyake, H. Yamamoto, Y. Fujiwara, M. Ohue, Y. Sugita, N. Tomita, M. Sekimoto, N. Matsuura, H. Shiozaki, and M. Monden Extensive Micrometastases to Lymph Nodes as a Marker for Rapid Recurrence of Colorectal Cancer: A Study of Lymphatic Mapping Clin. Cancer Res., May 1, 2001; 7(5): 1350 - 1357. [Abstract] [Full Text]